[EN] AMINOPYRROLOTRIAZINES AS KINASE INHIBITORS<br/>[FR] AMINOPYRROLOTRIAZINES EN TANT QU'INHIBITEURS DE KINASE
申请人:BRISTOL MYERS SQUIBB CO
公开号:WO2019147782A1
公开(公告)日:2019-08-01
The disclosure relates to compounds of formula I which are useful as kinase modulators including RIPK1 modulation. The disclosure also provides methods of making and using the compounds for example in treatments related to necrosis or inflammation as well as other indications.
Haloalkyl containing compounds as cysteine protease inhibitors
申请人:Link O. John
公开号:US20050182096A1
公开(公告)日:2005-08-18
The present invention is directed to compounds that are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, and S and are therefore useful in treating diseases mediated by these proteases. The present invention is directed to pharmaceutical compositions comprising these compounds and processes for preparing them.
Sulfonamide compounds as cysteine protease inhibitors
申请人:Woo Soon H.
公开号:US20090233909A1
公开(公告)日:2009-09-17
The present invention is directed to compounds of formula (I) that are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, and S and are therefore useful in treating diseases mediated by these proteases. The present invention is directed to pharmaceutical compositions comprising these compounds and processes for preparing them. Wherein R3 is -alkylene-SO2NR5R6.
Silinane compounds as cysteine protease inhibitors
申请人:Link O. John
公开号:US20070088001A1
公开(公告)日:2007-04-19
The present invention is directed to compounds that are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, and S and are therefore useful in treating diseases mediated by these proteases. The present invention is also directed to pharmaceutical compositions comprising these compounds and processes for preparing them. The present invention is also directed to the use of these inhibitors in combination with a therapy that causes a deleterious immune response in patients receiving the therapy.